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Applications of time-series analysis to mood fluctuations in
bipolar disorder to promote treatment innovation: a case series
EA Holmes1,2,3, MB Bonsall4,5, SA Hales3, H Mitchell1, F Renner1, SE Blackwell1, P Watson1, GM Goodwin3 and M Di Simplicio1
Treatment innovation for bipolar disorder has been hampered by a lack of techniques to capture a hallmark symptom: ongoing
mood instability. Mood swings persist during remission from acute mood episodes and impair daily functioning. The last significant
treatment advance remains Lithium (in the 1970s), which aids only the minority of patients. There is no accepted way to establish
proof of concept for a new mood-stabilizing treatment. We suggest that combining insights from mood measurement with applied
mathematics may provide a step change: repeated daily mood measurement (depression) over a short time frame (1 month) can
create individual bipolar mood instability profiles. A time-series approach allows comparison of mood instability pre- and post-
treatment. We test a new imagery-focused cognitive therapy treatment approach (MAPP; Mood Action Psychology Programme)
targeting a driver of mood instability, and apply these measurement methods in a non-concurrent multiple baseline design case
series of 14 patients with bipolar disorder. Weekly mood monitoring and treatment target data improved for the whole sample
combined. Time-series analyses of daily mood data, sampled remotely (mobile phone/Internet) for 28 days pre- and post-treatment,
demonstrated improvements in individuals’ mood stability for 11 of 14 patients. Thus the findings offer preliminary support for a
new imagery-focused treatment approach. They also indicate a step in treatment innovation without the requirement for trials in
illness episodes or relapse prevention. Importantly, daily measurement offers a description of mood instability at the individual
patient level in a clinically meaningful time frame. This costly, chronic and disabling mental illness demands innovation in both
treatment approaches (whether pharmacological or psychological) and measurement tool: this work indicates that daily
measurements can be used to detect improvement in individual mood stability for treatment innovation (MAPP).
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INTRODUCTION
For any disease or disorder, an essential part of treatment
development is the ability to measure and assess key clinical
outcomes. In the absence of appropriate techniques, innovation
will be slow. One example of where this problem has hampered
treatment development is bipolar disorder. Bringing together
ideas from several areas of science—here psychology, psychiatry
and applied mathematics—may provide an opportunity for
treatment advances.
Bipolar disorder (formerly ‘manic depression’) is characterized
by repeated episodes of depression with at least one (hypo)manic
episode of elevated mood and overactivity.1 The clinical picture is
that depression tends to dominate; therefore, depressed mood
fluctuations present the focus of this paper. Co-morbid anxiety is
common, fuelling depression, and relates to poorer prognosis.2
About 1% of adults have a lifetime history of bipolar I or II
disorder,3 which carries the highest rate of suicide of all psychiatric
disorders.4 The primary treatment is Lithium,5 a pharmacological
treatment established over 40 years ago,6 and satisfactory only for
a minority of patients.7,8 Despite research, treatment advance-
ment has been slow and a substantial proportion of patients
remain highly symptomatic. The development of new research
methods to support treatment innovation is critical.9,10
Treatment innovation for bipolar disorder has been hampered
by the lack of techniques to capture adequately one of its key
clinical features—ongoing mood swings (referred to as mood
instability henceforth) that can persist at a subsyndromal level.
There are several problems associated with traditional approaches
to bipolar disorder: an exclusive focus on full-blown illness
episodes; infrequent measurement; retrospective reporting biases;
and a lack of mathematical tools to capture mood over time.
Treatment advances with medication have been made on the
basis of studies of acute episodes (of depression or mania) and
longer term relapse prevention studies. The necessary programme
of clinical research is daunting and has rarely been attempted,
except, for example, by extending an existing marketing
authorization for schizophrenia, which offers a simpler develop-
ment path. By analogy, we contrast the current clinical picture in
bipolar disorder with advances for another chronic condition such
as diabetes, where ongoing monitoring of fluctuations in glucose
levels helps to prevent full-blown illness episodes. As yet, bipolar
disorder lacks the equivalent of more frequent glucose profile
monitoring.
Traditionally, outcome in bipolar disorder has focused on
infrequent measurements such as counting full-blown mood
episodes, which occur on average less than once per year.11 Such
a sampling rate takes a long time in the life of an individual
patient who would prefer to know in much shorter time frames
(days/weeks rather than months/years) how their illness is
progressing. Further, infrequent mood assessments over long
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time periods yields impoverished/noisy data. This problem has
bedeviled treatment trials for bipolar disorder, and as a result
some have had to be terminated early.12 Infrequent outcome
measurement bears the risk of failing to capture the real impact of
interventions and has driven recent efforts to develop more
ecologically valid outcome measures in pragmatic effectiveness
trials, such as frequency of clinical adjustments in medication.13
Assumptions about mental health treatment may be contributing
to the field being stuck. Simply taking a small number of
measurements pre- and post-treatment has worked well for other
mental health disorders (such as anxiety disorders) where
symptoms fluctuate less and a simple reduction in scores equates
with treatment success. However, bipolar disorder is different as
symptom reduction can be temporary and reverse (for example,
the next week or the next day), and a large reduction can even
herald greater instability to follow. Thus, more traditional
measurement approaches (for example, unitary measurements
pre- and post-treatment) commonly used in other psychiatric
disorders neglect bipolar patients’ difficulties with ongoing mood
instability.
A new approach for bipolar disorder is to focus on the chronic
subsyndromal ‘mood instability’ that persists in between full-
blown mood episodes,14,15 impairing daily functioning16,17 and
worsening long-term prognosis.18 Recent initiatives have mea-
sured mood weekly,19 but, various limitations have emerged. If the
frequency of mood swings is different from the sampling rate,
information can be missed (‘sparse sampling’).20 Memory is
mood-state-dependent,21 thus having to remember symptoms
from the past 7 days introduces a retrospective reporting memory
bias driven by current (fluctuating) mood state,21 particularly in a
disorder associated with memory deficits.22,23 Further, the number
of weekly data points needed to apply a time-series approach to
capture mood instability requires patients to comply with
monitoring for at least 6 months (with little missing data). This
is hard for a group where compliance with a regular regime
presents a core problem and long-term monitoring is onerous. At
an individual patient level, patients require a more rapid answer to
whether or not a new treatment is proving helpful, particularly so
when medication side effects can be burdensome,24 and where
unfortunately some antidepressant medications can precipitate
symptom worsening.25
Here, we suggest a bipolar treatment outcome measure of
ongoing mood instability using a daily sampling regime over
1 month in daily life, and further to analyse such mood data via an
applied mathematical time-series approach. This alternative
approach, that is, using mood data sampled daily to test for
improvements in mood instability over time, is less prone to
memory and mood biases than longer time intervals. It captures
ongoing symptoms in the real world rather than only in the clinic.
Daily sampling has proved effective as a self-monitoring tool.26
Here we adopt it for the first time as a method for improving
treatment outcome assessment. Sampling for 1 month is a
commonly used time frame in clinical practice (for example to
reveal when drug side effects become obvious to patient and
clinician)27 and could be incorporated in daily routines (via
technology such as smartphones). Time-series approaches28 allow
changes in mean mood and variability in mood to be properly
characterized. This provides a powerful way to extract differences
in mood profiles before and after treatment in patients with
bipolar disorder by evaluating whether differences in the good-
ness of fit of models have different time-series structures.28,29
It introduces mechanism into the understanding of mood
variability at the level of cognition (mechacognition).29 Ultimately,
this may promote more rapid examination of new early-stage
treatments, or treatment changes for an individual patient, by
targeting clinically meaningful ongoing and persistent subsyn-
dromal symptoms.
Here we investigate the use of a daily mood-monitoring time-
series approach in a single case series study of a novel treatment
for bipolar disorder. Single case series designs are important
research tools in the development of new treatments, providing
an alternative to cohort and case–control designs.30 They require
smaller sample sizes compared with randomized control trials,
as statistical power is provided by the within-subject comparison
of treatment effects.31–33 Moreover, single case series allow
for further refinement of treatment protocols at an exploratory
stage, when investment of time and resources required by
randomized control trials would be premature. They also
allow us to examine individual patient level data — our
clinical goal.
The broader clinical picture informing our choice of treatment
innovation concerns the high rates of anxiety that complicate
bipolar disorder, flagged by clinical guidelines as an unmet need
requiring treatment innovation.34 Anxiety symptoms are
associated with worse prognostic factors such as rapid mood
cycles, higher illness severity, less euthymic days and increased
suicidality,35 poorer functioning and worse treatment response.36
Unfortunately, pharmacological treatment for anxiety within
bipolar disorder has not been investigated formally and anti-
depressants may even destabilize mood, for example, inducing a
‘manic switch’.37 Psychological treatments such as cognitive
therapy offer adjunctive approaches for addressing anxiety in
bipolar disorder,38 but, like the use of antidepressants, often
represent extrapolation from uncomplicated anxiety disorders.
Anxiety in bipolar disorder should be of particular interest if, as
we have proposed, it contributes to depressed mood instability
via an ‘emotional amplifier’ effect of anxiety-laden mental
imagery.39
Mental imagery occurs when ‘perceptual information is
accessed from memory, giving rise to the experience of ‘seeing
with the mind’s eye’, ‘hearing with the mind’s ear’ and so on’.40
Recent findings suggest that imagery can have an important role
in the development and maintenance of various mental disorders,
including anxiety disorders.41 Traditional clinical assessments can
neglect asking patients about their intrusive upsetting mental
images,42 such as intrusive images of dreaded future events or
negative memories, images which can fuel anxiety and low mood.
A psychological treatment targeting such maladaptive imagery
could therefore improve anxiety and mood instability.39 Here
we test one such protocol (MAPP; Mood Action Psychology
Programme: clinicaltrials.gov identifier NCT01981018), which is an
imagery-focused cognitive therapy.
MAPP consisted of three distinct phases: first, an in-depth four-
session assessment was conducted in which a clinically significant
imagery-related anxiety target formulated to impact on mood
instability was jointly identified by the patient and co-therapists as
a treatment target. For example, an intrusive image of a past
stressful event, or a ‘flash-forward’ image to an anxiety-provoking
situation. Second, in the active treatment phase, imagery-based
psychological techniques were applied to address this treatment
target.43 Depending on the formulated target, aims of the
treatment phase included (1) transforming or dampening proble-
matic, destabilizing intrusive imagery via imagery rescripting or
competing visuospatial tasks; (2) changing the patient’s under-
standing of imagery, thereby reducing its impact via the use of
metacognitive techniques (for example, having an image of an
event does not mean it is real); (3) increasing access to positive,
mood-enhancing or soothing imagery using positive imagery
strategies (for example, compassionate self-view of looking after
oneself in the future). The treatment focus was on learning a small
number of techniques well. Techniques were tailored to break
patients’ bespoke symptoms cycles, with the aim of preventing
future anxiety and mood extremes. Third and finally, a consolida-
tion phase was designed to enhance learning and recall of the
treatment, and included creation of a video ‘blueprint’ to act as a
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record of the main learning outcomes for the patient to refer back
to in the future and potentially share with others.
Using a non-concurrent multiple baseline design case series
of 14 patients with bipolar disorder who undertook the new
treatment, we hypothesized that this novel treatment (MAPP)
would lead to the following:
● for the whole sample combined, reductions in mean levels of
mood and anxiety (weekly and daily), as well as improved daily
mood instability (that is, a more regular temporal structure)
over the new treatment;
● an improvement at the individual patient level, whereby daily
mood instability profiles would become more stable over
treatment.
The study assessed adherence to daily mood monitoring. In
addition, we examined whether mood improvement was
mediated by changes in the psychological treatment target
(imagery). A further outcome measure was relapses assessed by
clinical interview at 24 weeks post-treatment versus pre-treatment
(for additional clinical measures and associated results, see
Supplementary Materials). Overall, there are two forms of
innovation in the current study: an examination of a novel
treatment (MAPP), and a new measurement tool for individual
mood instability (daily mood monitoring).
MATERIALS AND METHODS
Experimental design
A non-concurrent multiple baseline design, with a series of A-B replications
was used.32,44 Fourteen patients with bipolar disorder were randomly
assigned to 4, 5 or 6 weeks baseline (n= 5, 4 and 5, respectively) using a
blocked randomization procedure by an independent researcher. Weekly
mood monitoring was completed via a web-based system throughout
baseline and continued until 24 weeks post-treatment. Daily mood
monitoring measures were completed via the web-based system for two
time periods: the last four baseline weeks (pre-treatment),45 and the
4 weeks immediately after ending treatment (post-treatment). To allow
assessment of the structure of the correlation in the time-series,
participants were required to complete a minimum of 23/28 daily
assessments at baseline for inclusion into the study (pre-specified). Pen-
and-paper measures were completed at five face-to-face assessments: at
pre-treatment, at the end of treatment, and at the 4, 12 and 24 weeks
follow-ups. Thus, there were pre-defined end points and rules for stopping
data collection. To reduce bias, an assessor other than the treatment
therapists completed the outcome assessments.
Sample size was pre-specified as 15 cases (clinicaltrials.gov identifier
NCT01981018), based on pilot results leading to an effect size estimate of
d= 0.8. Recruitment was via referral from local mental health services.
Interested participants underwent a face-to-face eligibility assessment
(n=28). Recruitment stopped once 15 met inclusion criteria. One person
withdrew after two sessions due to severe side effects of Lithium
precluding further involvement. The final sample comprised 14 patients
(Table 1 and Supplementary Table S1). Further details of recruitment and
screening are provided in the Supplementary Materials. Ethical approval
was granted by NRES Committee East of England — Essex (13/EE/1074).
Informed consent was obtained from all the participants after the nature
and possible consequences of the study were explained.
Research objectives
The study aimed to investigate the delivery and efficacy of a new cognitive
therapy treatment for bipolar disorder (imagery-focused), studying
patients one-by-one in a ‘case series’ and assessing their mood over time.
The primary outcome measures were pre-specified as change in weekly
scores of anxiety, Beck Anxiety Inventory (BAI),46 and depression, Quick
Inventory of Depressive Symptomatology Self-Report (QIDS-SR),47 over
treatment: clinicaltrials.gov identifier NCT01981018. Pooled scores from
aggregated time points over the 4 weeks after treatment (post-treatment)
were compared with aggregated time points over the pre-treatment
baseline (weekly QIDS-SR and BAI).
We sought to examine, for all participants combined, whether their
mean aggregated daily mood and anxiety improved from pre- to post-
treatment, and whether the temporal structure of mood scores improved
— calculated as a time-series profile of daily mood on the QIDS-SR scale
(based on earlier work over a broader time scale).28 Further, we aimed to
analyse individual patient time-series mood profiles for improvements in
mood instability and transition between mood states. We examined
whether imagery treatment target ratings were associated with changes in
the primary outcome measures.
To confirm that there was no significant reduction in symptoms pre-
treatment, consistency of depression and anxiety was assessed over the
baseline period. Adherence to daily monitoring was assessed for 28 days
pre- and post-treatment.
Additional objectives were to assess intervention effects on clinical
relapses of mania and depression, and anxiety co-morbidity, as well as self-
reported affective lability, impairments in functioning, hopelessness and
suicidality, and medication compliance (see Supplementary Materials).
Table 1. Baseline characteristics of the study cohort (N= 14) including
demographic details, bipolar diagnosis, comorbidities and illness
variables, and medication
Category n (%)/mean (s.d.)
Demographic characteristics
Age at study intake, years, mean (s.d.) 37.00 (11.82)
Gender, n (%)
Female 12 (86)
Male 2 (14)
Ethnicity, n (%)
White British 11 (79)
White other 3 (21)
Clinical characteristics
Bipolar disorder, n (%)
Type 1 9 (64)
Type 2 5 (36)
DSM-5 anxiety specifier, n (%)
Mild 4 (29)
Moderate 4 (29)
Moderate–severe 6 (43)
Comorbidity and clinical course, n (%)
History of psychosis 3 (21)
Current depressive episode 7 (50)
Current comorbid anxiety disorder 9 (64)
Past comorbid anxiety disorder 3 (21)
History of other Axis I disorders 5 (36)
Bipolar illness variables, mean (s.d.)
Age at illness onset, years 21.07 (10.48); range: 7–48
Number of depressive episodes
(past 6 months)
1.29 (0.83); range: 0–3
Duration of depressive episodes
(past 6 months) in weeks
11.67 (6.39); range: 5–20
Number of (hypo)manic episodes
(past 6 months)
0.79 (0.89); range: 0–3
Duration of (hypo)manic episodes
(past 6 months) in weeks
3.13 (2.03); range 1–6
Number of suicide attempts
(lifetime)
0.86 (1.46); range: 0–5
Number of hospitalizations (lifetime) 0.93 (2.37); range: 0–7
Number of depressive episodes
(lifetime), n (%)
0–4 episodes 4 (29)
5–9 episodes 2 (14)
410 episodes 8 (57)
Medication at screening, n (%)
Lithium 6 (43)
Anticonvulsants 5 (36)
Antipsychotics 5 (36)
Antidepressants 3 (21)
None 1 (7)
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Measures
Weekly mood monitoring. Depressive symptom severity over the past
7 days was assessed using the QIDS-SR,47 a 16-item questionnaire covering
the nine DSM IV-TR48 major depressive disorder symptoms. Ratings are
made on a four-point scale (0–3) anchored at all points by a description.
For example, Question 11, ‘view of myself’ is anchored at 0 = ‘I see myself
as equally worthwhile and deserving as other people’, 1 = ‘I am more self-
blaming than usual’, 2 = ‘I largely believe that I cause problems for others’
and 3= ‘I think almost constantly about major and minor defects in myself’.
Following local ethics committee advice, item 12 ‘thoughts of death or
suicide’ was removed from the online mood monitoring (weekly and daily).
Note: the complete scale including suicide item was used for face-to-face
assessments. The QIDS-SR correlates highly with established clinician
rating scales such as the Hamilton Rating Scale of Depression (r = 0.86) and
has high internal consistency (α=0.87).47
Anxiety symptom severity over the past 7 days was measured using the
BAI,46 comprising 21 items. Ratings are made on a four-point scale (0–3)
from ‘not at all’ to ‘severely’. Example items include ‘scared’, ‘fear of losing
control’ and ‘heart pounding or racing’. The BAI has high internal
consistency (α= 0.92) and test–retest reliability over 1 week, r=0.75.49
Daily mood monitoring. Depressive symptoms were assessed using a
modified version of the QIDS-SR47 anchored to the last 24 h. The suicide
item was again removed, as were two items referring to an unfeasible time
frame for a daily rating—‘decreased/increased weight within the last
14 days’, yielding 13 items. The structure of the daily QIDS-SR scoring is
appropriate for time-series analysis with Gamma errors (see
Supplementary Materials and also ref. 28). For further individual patient
analysis of the time-series (using Markov chains — see the methods
below), the cut-off score for moderate depression on the original QIDS-SR
(⩾11)47 was adapted to ⩾ 9 to account for the omitted items.
Daily anxiety symptoms were assessed via two bespoke ratings on a
similar scale: the extent to which the participant felt anxious and fearful,
and the severity of physical anxiety symptoms.
Computerized monitoring system. The computerized monitoring system
was implemented via two secure servers: a web server hosting the website
for completing questionnaires, and a database server to generate
automatic prompts. Automated prompts were sent via email to all the
participants (N=14), and by a mobile phone short message service where
requested (N=12). If a participant did not complete a weekly or daily
measure online within the scheduled time frame, researchers would
attempt to contact them to complete the measure at the earliest
opportunity, either via the online system, phone or at a therapy session.
At pre- and post-treatment combined, 27 outstanding primary outcome
weekly assessments (of 504, that is, 5.36%) and 34 outstanding
daily assessments (of 784, that is, 4.34%) were collected following this
procedure.
Additional measures. Measures taken at the face-to-face pre- and post-
treatment assessments and weekly scores of mania symptoms are
reported in the Supplementary Materials.
Treatment
The imagery-focused treatment consisted of three phases: an in-depth
assessment (four sessions—‘mapping’), active treatment and consolidation
(in total 10–14 sessions, including mapping). During the fourth and final
assessment session, the patient and co-therapists jointly agreed on a
clinically significant target for imagery-focused cognitive therapy, for
example, ‘destabilizing’ imagery-related anxiety or lack of positive imagery.
Choice of target was based on the following criteria: (1) the symptom was
a valid target in its own right (that is, it was distressing or destabilizing), (2)
it was formulated to have a plausible link to mood instability and (3) it was
judged to be tractable in a brief imagery-focused cognitive therapy
intervention. The active treatment phase (~4–6 sessions) selected imagery
intervention strategies, either alone or in combination: metacognitive,
imagery rescripting, positive imagery and competing tasks. Metacognitive
strategies teach the patient to view images as merely mental representa-
tions (‘an image is just an image’) rather than imbued with emotional
meaning. Imagery rescripting helps the patient to transform distressing or
maladaptive images into more benign, functional ones.50 Positive imagery
strategies involve the creation and practice of mood-enhancing,51
or soothing images.52 Imagery competing strategies use concurrent
visuospatial tasks (such as a computer game) to dampen problematic
imagery.53,54 In the consolidation of learning phase (two sessions),
patients made a video record of important parts of their therapy. Two
co-therapists were present in all the sessions (sometimes one remotely via
Skype).
Participants attended a mean of 11.6 sessions of therapy including the
assessment in the mapping phase, active treatment and consolidation (s.
d. = 1.22; range 10 to 14), with a mean duration of 15.6 weeks (s.d. = 2.77;
range= 11 to 22).
MAPP Manual
The treatment followed a manual developed by mental health clinicians
with expertise in bipolar disorder and Cognitive Behavioural Therapy, with
feedback from clinicians external to the project and patients with bipolar
disorder.
Statistical analysis
Data completion at face-to-face assessments. All the 14 participants took
part in the face-to-face assessments at pre-treatment baseline and end of
treatment, 4, 12 and 24 weeks post-treatment. At the end of treatment
assessment, one participant did not complete the questionnaires
(missing data).
Weekly mood-monitoring scores. The comparison of average weekly
baseline scores (QIDS-SR and BAI) with those at follow-up were conducted
using paired two-tailed t-tests, following checking of the distributions of
difference scores. Pooled weekly scores from aggregated time points over
the pre-treatment baseline were compared with aggregated time points
over the four weekly scores post-treatment. Note pre-treatment baseline
was randomized as 4, 5 or 6 weeks (see Experimental Design).
Missing values for the primary outcome weekly measures were low:
1 of 70 QIDS-SR assessments at baseline (completion rate 98.57%).
At post-treatment, 2 of 56 QIDS-SR were missing (completion rate 96.43%).
At baseline, 2 of 70 BAI assessments were missing (completion rate
97.14%). At post-treatment, 2 of 56 BAI were missing (completion rate
96.43%).
Daily mood monitoring
Daily mood and anxiety scores. The comparison of average daily baseline
scores (QIDS-SR and anxiety ratings) with those at follow-up were
conducted using paired t-tests (two-tailed), following checking of the
distributions of difference scores. Each assessment questionnaire incorpo-
rates both scales. Missing values for the daily measures were low: at
baseline, 17 of 392 assessments were missing (completion rate 95.66%). At
post-treatment, 17 of 392 assessments were missing (completion rate
95.66%). Overall completion rate was 750 out of 784 (95.66%).
Daily mood profiles. For further details of the time-series analysis on daily
mood profile described in the Results, see also Supplementary Materials.
Effect sizes. Effect size (Cohen’s d) was calculated by dividing the mean
difference by the pooled s.d.55 Effect sizes of nonparametric tests were
calculated by computing r= z/SQRT(n) (ref. 56) and r was converted to d
using the following formula: d= (2 × r)/SQRT(1− r2).57
Outliers. Analysis of outliers was incorporated into analysis of the
normality of residuals obtained from the fitting of parametric t-tests and
analysis of variance and the associated use of nonparametric tests, as
required. No outliers were excluded. If there was skewness, they were
downweighted using nonparametric tests.
Time-series. Correlation structures across the pre- and post-treatment time
periods were analysed using time-series analysis following Bonsall et al.28
On the basis of a conditional-likelihood framework (see Supplementary
Materials), we fitted linear and nonlinear (threshold based) autoregressive
(AR) models to the mood scores before and after treatment. A linear
autoregressive model with a single lag (referred to as AR(1) model) takes
the form:
Yt ¼ a0 þ a1Yt - 1
where Yt is the mood score on the current day (at time t) and Yt− 1 is the
mood score from the previous day (at time t− 1). a0 and a1 are unknown
parameters (to be statistically estimated). A threshold autoregressive
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model (with a single lag—referred to as a threshold autoregressive
structure (TAR(1)) model) takes the form:
Yt ¼ a0 þ a1Yt - 1 ifYtXYa2 þ a3Yt - 1 ifYt <Y

where Y is the mean of the mood score and the model has different
parameters ([a0, a1] or [a2, a3]) above and below this mean mood score.
The distribution of mood scores is non-normal and in the Supplementary
Materials (and elsewhere28) we have shown that these scores are well-
characterized by a Gamma distribution. We use this probability distribution
to construct an appropriate conditional likelihood (see Supplementary
Materials). Computationally, we minimize the negative log-likelihood using
an expectation-maximization method to deal with missing values (outliers)
within a modified simplex optimization algorithm implemented in C. Using
the Akaike Information Criterion,58 we evaluate the goodness of fit of four
different time-series models: AR(1), AR(2), TAR(1) and TAR(2) to the pooled
participant pre- and post-treatment time-series. We also determine one-
step-ahead predictions for each time-series based on the overall best fit
pre- or post-treatment time-series model.
Markov chain analysis. Individual variation in QIDS-SR scores was
analysed as a Markov chain stochastic process. We group QIDS-SR scores
into three countable values (0, o9, ⩾ 9) and determine the transition
probability from a QIDS-SR score on day t to a QIDS-SR score on day t+1.
This gives a 3 × 3 one-step transition matrix:
t þ 1t
P0;0 P0;<9 P0;X9
P<9;0 P<9;<9 P<9X9
PX9;0 PX9;<9 PX9;X9
0
@
1
A ð1Þ
where each entry, Px,y, is a transition probability from one day to the next;
for example, P0,0 is the probability that given a QIDS-SR score = 0 on day t,
the QIDS-SR score on day t+1 is also 0; and Po9,0 is the probability that
given a QIDS-SR score o9 on day t, the QIDS-SR score on day t+1 is 0.
For each participant, we determine transition matrices for probability of
changes in QIDS-SR scores pre- and post-treatment. Using standard
methods of analysis,59 we solve these matrices for the stationary
probabilities of QIDS-SR score states pre- and post-treatment.
Code availability
Scripts used for the time-series and Markov chain analyses are available on
request from the second author (MBB).
RESULTS
Patient characteristics
The characteristics of the study cohort are shown in Table 1 and
Supplementary Table S.1.
Treatment intervention reduces weekly mood monitoring scores
Pooled weekly scores (depression/anxiety) from aggregated time
points over the pre-treatment baseline (4/5/6 weeks) were
compared with aggregated time points over the corresponding
four weekly scores post-treatment (primary outcome measures:
see Materials and methods; Experimental design).
Paired two-tailed t-tests confirmed that there was a significant
reduction in both patients' mean depression, QIDS-SR,47 and
anxiety scores, BAI,46 from pre- to post-treatment, see Table 2 (and
Supplementary Figure S.1. for individual level data including 6-
month follow-up).
During the pre-treatment baseline (alone), symptoms of
depression (QIDS-SR) and anxiety (BAI) showed no indication of
spontaneously improving over time (see Supplementary Results;
weekly mood-monitoring scores remain consistent over the pre-
treatment baseline periods). This indicates that the observed
effects at post-treatment are more likely owing to the intervention
rather than the passage of time.
Daily mood monitoring adhered to for 28 days pre- and
post-treatment
All the patients successfully completed pre-treatment baseline
monitoring (that is, at least 23 out of 28 daily mood measures) in
the 4-week active run-in phase of the study, indicating excellent
adherence (M= 26.79, s.d. = 1.42). Likewise, all patients successfully
completed post-treatment daily mood monitoring (M= 26.79, s.
d. = 1.97).
Treatment intervention reduces mean daily mood-monitoring
scores
Paired two-tailed t-tests showed significant reductions in mean
daily QIDS-SR and anxiety scores in the 28 days pre-treatment
versus post-treatment, see Table 3.
Henceforth, we focus on daily QIDS-SR for our analysis of mood
instability; see Materials and methods for psychometric properties
relevant to the time-series.
Treatment intervention affects temporal structure of daily mood
profiles: aggregated patient analysis
Aggregate mood profiles before and after treatment showed
different temporal dynamics. Our time-series analysis through
appropriate model selection using Akaike Information Criterion
(see, Supplementary Figure S.2.) revealed that before treatment
the aggregate mood profiles were most appropriately described
Table 2. Weekly depression (QIDS-SR) and anxiety (BAI) scores for the 14 participants combined, aggregated over the pre-treatment baseline
(4/5/6 weeks) and over the post-treatment (4 weeks) period
Outcome measure Pre-treatment (mean± s.d.) Post-treatment (mean± s.d.) t(df), P-value Cohen's d
Weekly QIDS-SR 8.94± 3.55 4.41± 2.87 t(13)= 3.86, P= 0.002 d= 1.40
Weekly BAI 13.71± 4.37 4.80± 5.02 t(13)= 6.55, Po0.001 d= 1.89
Abbreviations: BAI, Beck Anxiety Inventory; QIDS-SR, Quick Inventory of Depressive Symptomatology Self-Report.
Table 3. Daily mood scores (QIDS-SR and anxiety ratings) for all 14 participants combined, aggregated over 28 days pre-treatment and 28 days
post-treatment
Outcome measure Pre-treatment (mean± s.d.) Post-treatment (mean± s.d.) t(df), P-value Cohen's d
Daily QIDS-SR 7.19± 3.55 3.79± 2.59 t(13)= 2.99, P= 0.010 d= 1.09
Daily anxiety 1.77± 0.62 0.87± 0.82 t(13)= 4.64, Po0.001 d= 1.24
Abbreviation: QIDS-SR, Quick Inventory of Depressive Symptomatology Self-Report.
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with a TAR model. TAR models represent a class of time-series
models that characterize dynamics that have complex correlation
structures and as such are likely to predict highly nonlinear
changes in mood scores. Across the 14 patients, the TAR model
predicts different mood dynamics above and below a threshold
(in our case the mean) QIDS-SR score and gives rise to daily mood
profiles that are highly variable (Figure 1). Pre-treatment, the
patient time-series were appropriately described with four
parameters based on two previously reported daily mood scores
to predict current mood score (see Supplementary Table S.2.).
Post-treatment, the aggregate mood profiles were approxi-
mated with a simpler, less complex, time-series model that only
required two parameters based on two previously reported daily
mood scores to predict current mood score (see Supplementary
Table S.2.). That is, the mood dynamics no longer differed above
and below a mean QIDS-SR score.
Treatment intervention affects individual daily mood-instability
profile
Time-series models derived from aggregated scores of all 14
patients were fitted to individual patients. Comparisons of these
individual mood profiles before and after treatment (together with
goodness of fit criteria) for the pre-treatment model (TAR(2)) and
the post-treatment model (AR(2)) are shown in Figure 1.
Mood profiles before and after treatment showed changes in
the overall instability pattern (see Supplementary Table S.3.). To
investigate how changes in the temporal structure affected the
mood profile, the probability of moving between different mood
states, we determined the probability transitions between three
QIDS-SR score states (zero, mild and moderate levels), (see
Materials and methods; Daily mood monitoring). At an individual
patient level, our analysis revealed a general increase in the
probability of observing patients with low QIDS-SR scores (o9)
after treatment and a reduction in the probability of high QIDS-SR
scores (⩾9). Individual patient analyses were possible given the
appropriate monitoring before and after treatment, and the
details of this approach (using a Markov chain analysis) and the
results for each patient are reported in Figure 2 (and individual
level data in Supplementary Table S.3.). Figure 2 shows the general
patterns of changes in the long-term probabilities of QIDS-SR
scores in each of the three states (zero, mild and moderate levels)
before and after treatment per patient. This analysis showed that
in 11 of 14 cases, there was an improvement in mood profiles with
a decreased occurrence of high QIDS-SR scores (49), and hence
less time spent above the clinical cut-off for depressed mood.
Further, 7 out of 14 patients had more zero QIDS-SR scores post-
treatment, and hence had no reported mood dysfunction (see
Figure 2).
DISCUSSION
Bipolar disorder, a severe and chronic illness, urgently needs the
rapid development of novel treatments and measurement
innovations. Subsyndromal mood instability is a key clinical factor
impacting on the long-term course of bipolar disorder; however, it
has remained a neglected treatment target, and techniques to
measure mood instability are lacking. Our study showed that time-
series analysis of mood scores collected daily for 1 month can
capture mood instability, and its improvement, in a case series of
patients with bipolar disorder. The clinical application of
mathematical approaches may open solutions to a critical clinical
challenge, highlighting the benefit of translating advances from
other disciplines to treatment innovation in mental health.10
Our study cohort showed excellent adherence to the daily
mood sampling regime both pre- and post-treatment, suggesting
that this is a viable strategy in bipolar disorder. Monitoring in daily
life may help avoid the memory biases inherent when reporting
over longer time intervals (for example, weekly or at clinic
appointments). One participant stated ‘[I] liked the daily one, [but]
found the weekly one unhelpful as it is very difficult to remember
a whole week’; another participant stated ‘psychiatrists always ask
when is the last time you felt like this – but they don’t give you the
tools to answer it, it’s all based on memory and memory is the
least reliable aspect here…when you are sick the memory itself is
distorted’. A longitudinal time-series approach, as developed here,
may help in part to redress these sorts of patient concerns.
Time-series models enabled us to obtain a reliable representa-
tion of subsyndromal mood instability aggregated over the whole
group, and at an individual patient level. At the aggregated level
across the whole group, we show that time-series differences in
mood score occur before and after treatment. Clinically, before
treatment, patients had complex correlated mood scores
(described statistically with a threshold autoregressive TAR(2)
model). After treatment, patients had simpler, less variable mood
dynamics (described by autoregressive (AR(2)) model). As such
and potentially clinically, for an individual patient (and those
around them) post-treatment, it may be sufficient to predict mood
dynamics with a few symptoms and/or based on data collected
over a smaller number of days than compared with pre-treatment
conditions (see Figure 1).
At the individual patient level, Markov chain analysis provided
descriptions of treatment effects in terms of time spent in a given
mood state, and likelihood of transitions between mood states.
The associated figures for each patient provide a simple
demonstration of the probabilistic transition between the three
types of mood states (absent/mild/moderate depressive symp-
toms, see Figure 2). Providing patients with such representations
could help better understanding of their own mood symptoms (a
critical demand of bipolar patients) and reinforce treatment
adherence, a major obstacle in this population. Such tools could
allow symptom improvement/deterioration to be checked by
clinician or the patient themselves.
The case series suggests that the novel therapy (MAPP: imagery-
focused cognitive therapy) may be a promising treatment for
further development, reducing mood instability for 11/14 patients,
and improving mood and anxiety symptoms at a group level. The
anxiety reduction is encouraging as this is an unmet need in
bipolar disorder, supporting the idea that reducing anxiety may
provide a route to reducing mood instability. The high attendance
rate speaks about the intervention’s acceptability. The improve-
ment in mood instability shown by the less complex temporal
structures of mood profiles post-treatment is reinforced by
convergent improvements on more traditional measures
(Supplementary Table S.4.). Secondary outcomes analyses suggest
potential utility of the therapy on functional as well as clinical
outcomes. Finally, our analyses of therapeutic mechanisms
suggest changes in the treatment target — emotional imagery
— were associated with symptom change (Supplementary
Materials).
We note that the main aim of this paper is not to make an
argument about treatment efficacy, but rather to demonstrate the
mathematical approach used. Within this longitudinal framework,
the single case series method provides the best design to
demonstrate the applicability of this methodological innovation at
the level most relevant to clinical care—that of the individual
patient. An appropriate control is provided by the time-series
before treatment. Limitations of the study include that this was a
case series with a small sample size, and no parallel control
condition. However, the absence of spontaneous improvement
during the pre-treatment baseline (Supplementary Materials)
indicates that symptom reduction over treatment was unlikely
to be simply owing to the passage of time. Unlike in other
psychiatric disorders, mood trajectories are not expected to
improve spontaneously in bipolar disorder60 as instability is persi-
stent and mood constantly fluctuates.19,61,62 Another limitation is
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Figure 1. The QIDS-SR daily mood scores for 28 days pre-treatment (left hand side) and 28 days post-treatment (right hand side), per
participant. Participants presented in order of starting mood monitoring. Individual mood plots show the QIDS-SR score (black points and
black line), best model fit from time-series analysis (purple points). Predicted values (from the overall time-series model pre- and post-
treatment) are shown with an approximate 95% CI band in grey. Note, differing y axis are used for visibility of any change in variability of the
daily ratings (and see Supplementary Figure S1 for mean weekly values pre- and post-treatment). CI, confidence interval; QIDS-SR, Quick
Inventory of Depressive Symptomatology.
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that perhaps daily mood monitoring itself promoted well-being,
and this could be tested in future research. The sample is not
representative of the wider population, comprising mainly females
who were Caucasian, studying or in work, thus caution must be
drawn in generalizing from results. However, overall, case series
designs are useful at the early stages of treatment innovation
where a larger clinical trial is not yet warranted and a detailed
individual patient picture useful.63 Future studies could include
comparative-efficacy and cost-effectiveness testing. Finally,
whether improvements in mood instability measured over 4 weeks
of daily monitoring are predictive of longer term outcomes
beyond the 24-week follow-up, remains to be tested.
Participant 13          
Participant 1 
Participant 5 
Participant 9 
Participant 2 
Participant 6 
Participant 10 
Participant 14 
Participant 3 
Participant 7 
Participant 11 
Participant 4  
Participant 8 
Participant 12
Figure 2. Markov chain analysis of changes in QIDS-SR daily scores for individual participants pre- and post-treatment. Circle size represents
the probability of a patient being in a certain mood state: red circles represent moderate levels of depression (QIDS-SR⩾ 9); orange circles
represent mild levels of depression (QIDS-SR⩽ 9 and not equal to 0); green circles represent the absence of any depressive symptoms (QIDS-
SR= 0). For a given participant, this gives a picture of transition between states during their 28-day baseline phase (front triangle) which can
be compared with their 28-day post-treatment phase (back triangle).
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We believe that a time-series analysis of daily mood scores
collected in everyday life could provide a template for exploring
individualized behavioural markers of treatment response. Sub-
syndromal mood instability is a critical outcome for bipolar
disorder in its own right. New measurement approaches64,65 could
be applied to any type of bipolar treatment whether pharmaco-
logical or psychological. As the quest for biomarkers in bipolar
disorder remains problematic, our proposed method of using
easy-to-collect computerized/mobile phone self-report data with
the aid of probability mathematical models is a pragmatic step. It
is noninvasive and inexpensive compared with developing
alternatives using neuroimaging or blood sampling for inflamma-
tory markers. It allows development of bespoke time-series that
capture clinically meaningful mood instability patterns at the
individual level. Future research might seek to consider other
disorders characterized by mood instability (for example, border-
line personality disorder), or other mood monitoring time
schedules ideally based on individual patient need. Extension to
preventative mental health, given that children and young people
with subsyndromal mood instability have a higher risk for
developing bipolar disorder,18,61 will also be crucial. Critically,
however, compared with existing methods that require months
(via weekly mood monitoring) or even years (via relapse or
hospitalization rates) before the efficacy of a treatment can be
evaluated, the current approach requires only 1 month of data
to assess mood instability. This may provide a useful tool to
accelerate the much-needed treatment innovation for bipolar
disorder.
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